Olema Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30 p.m. ET in New York, and the T.D. Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 5 p.m. ET in a virtual format. Both presentations will be in a fireside chat format. Live webcasts and recordings will be accessible through Olema's investor relations website at ir.olema.com.

News Market Reaction – OLMA

+3.48%

1 alert

+3.48% News Effect

On the day this news was published, OLMA gained 3.48%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

H.C. Wainwright 3^rd Annual BioConnect Investor Conference
Date: Tuesday, May 20, 2025 at 4:30 p.m. ET
Format: Fireside Chat
Location: New York, NY

T.D. Cowen 6^th Annual Oncology Innovation Summit: Insights for ASCO and EHA
Date: Tuesday, May 27, 2025 at 5 p.m. ET
Format: Fireside Chat
Location: Virtual

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When is Olema Pharmaceuticals (OLMA) presenting at the H.C. Wainwright BioConnect Conference?

Olema Pharmaceuticals will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025, at 4:30 p.m. ET in New York.

Where can I watch Olema Pharmaceuticals' (OLMA) investor conference presentations?

Live webcasts and recordings of the presentations will be available on Olema's investor relations website at ir.olema.com in the Events and Presentations section.

What is Olema Pharmaceuticals' (OLMA) main focus area?

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond.

When is Olema Pharmaceuticals (OLMA) presenting at the T.D. Cowen Oncology Innovation Summit?

Olema Pharmaceuticals will present at the T.D. Cowen Oncology Innovation Summit on Tuesday, May 27, 2025, at 5 p.m. ET in a virtual format.